BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,366,726 | +41.1% | 317,282 | -8.0% | 0.00% | +50.0% |
| Q2 2023 | $5,928,737 | +123.5% | 344,694 | +115.4% | 0.00% | +100.0% |
| Q1 2023 | $2,652,999 | +544.1% | 160,012 | +196.0% | 0.00% | – |
| Q4 2022 | $411,921 | +104.9% | 54,058 | +167.9% | 0.00% | – |
| Q3 2022 | $201,000 | -72.5% | 20,175 | -75.0% | 0.00% | – |
| Q2 2022 | $731,000 | -76.0% | 80,548 | -73.2% | 0.00% | -100.0% |
| Q1 2022 | $3,045,000 | -83.9% | 300,092 | -73.5% | 0.00% | -83.3% |
| Q4 2021 | $18,884,000 | +159.7% | 1,132,137 | +629.8% | 0.01% | +100.0% |
| Q3 2021 | $7,271,000 | +0.7% | 155,140 | +31.0% | 0.00% | +50.0% |
| Q2 2021 | $7,221,000 | +39.5% | 118,462 | +41.0% | 0.00% | -33.3% |
| Q1 2021 | $5,175,000 | +5.9% | 84,012 | +22.3% | 0.00% | +50.0% |
| Q4 2020 | $4,885,000 | +334.2% | 68,690 | +129.1% | 0.00% | +100.0% |
| Q3 2020 | $1,125,000 | -23.5% | 29,983 | -33.5% | 0.00% | 0.0% |
| Q2 2020 | $1,470,000 | – | 45,077 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |